29th Jun 2015 07:00
Blocklisting Six Monthly Return
London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) announces the following blocklisting six monthly return:
1. | Name of applicant:
| Hutchison China MediTech Limited | |
2. | Name of scheme:
| Hutchison China MediTech Limited Share Option Scheme
| |
3. | Period of return:
| From 29 December 2014 to 28 June 2015 | |
4. | Balance under scheme from previous return:
| 696,051 ordinary shares of US$1 each
| |
5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
| Nil | |
6. | Number of securities issued/allotted under scheme during period: | 223,288 ordinary shares of US$1 each | |
7. | Balance under scheme not yet issued/allotted at end of the period:
| 472,763 ordinary shares of US$1 each | |
8. | Number and class of securities originally listed and the date of admission:
| 2,560,606 ordinary shares of US$1 each admitted on 26 June 2007 | |
9. | Total number of securities in issue at the end of the period: | 53,299,964 ordinary shares of US$1 each | |
Name of contact:
| Christian Hogg | ||
Address of contact:
| 21/F., Hutchison House, 10 Harcourt Road, Hong Kong
| ||
Telephone number of contact:
| +852 2121 8200 |
Ends
Enquiries
Chi-Med Christian Hogg, CEO | Telephone: +852 2121 8200
|
Panmure Gordon (UK) Limited | Telephone: +44 20 7886 2500 |
Richard Gray Andrew Potts |
|
Citigate Dewe Rogerson Anthony Carlisle David Dible | Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919 |
About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:1). For more information, please visit: www.chi-med.com.
Related Shares:
Hutchmed